BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pellegrini C, Fornai M, Colucci R, Benvenuti L, D’Antongiovanni V, Natale G, Fulceri F, Giorgis M, Marini E, Gastaldi S, Bertinaria M, Blandizzi C, Antonioli L. A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation. Front Pharmacol 2018;9:1405. [PMID: 30559669 DOI: 10.3389/fphar.2018.01405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Lu Q, Yang M, Liang Y, Xu J, Xu H, Nie Y, Wang L, Yao J, Li D. Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics. JIR 2022;Volume 15:1825-44. [DOI: 10.2147/jir.s353038] [Reference Citation Analysis]
2 Osorio C, Kanukuntla T, Diaz E, Jafri N, Cummings M, Sfera A. The Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling. Front Aging Neurosci 2019;11:143. [PMID: 31297054 DOI: 10.3389/fnagi.2019.00143] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
3 Antonioli L, Lucarini E, Lambertucci C, Fornai M, Pellegrini C, Benvenuti L, Di Cesare Mannelli L, Spinaci A, Marucci G, Blandizzi C, Ghelardini C, Volpini R, Dal Ben D. The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis. Cells 2020;9:E1509. [PMID: 32575844 DOI: 10.3390/cells9061509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Fusco R, Siracusa R, Genovese T, Cuzzocrea S, Di Paola R. Focus on the Role of NLRP3 Inflammasome in Diseases. Int J Mol Sci 2020;21:E4223. [PMID: 32545788 DOI: 10.3390/ijms21124223] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 22.0] [Reference Citation Analysis]
5 Ngui IQH, Perera AP, Eri R. Does NLRP3 Inflammasome and Aryl Hydrocarbon Receptor Play an Interlinked Role in Bowel Inflammation and Colitis-Associated Colorectal Cancer? Molecules 2020;25:E2427. [PMID: 32456012 DOI: 10.3390/molecules25102427] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Chen QL, Yin HR, He QY, Wang Y. Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease. Biomed Pharmacother 2021;138:111442. [PMID: 33667791 DOI: 10.1016/j.biopha.2021.111442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Shi Y, Lv Q, Zheng M, Sun H, Shi F. NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages. Int Immunopharmacol 2021;92:107358. [PMID: 33508701 DOI: 10.1016/j.intimp.2020.107358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Coll RC, Schroder K, Pelegrín P. NLRP3 and pyroptosis blockers for treating inflammatory diseases. Trends Pharmacol Sci 2022:S0165-6147(22)00083-9. [PMID: 35513901 DOI: 10.1016/j.tips.2022.04.003] [Reference Citation Analysis]
9 Gastaldi S, Boscaro V, Gianquinto E, Sandall CF, Giorgis M, Marini E, Blua F, Gallicchio M, Spyrakis F, MacDonald JA, Bertinaria M. Chemical Modulation of the 1-(Piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one Scaffold as a Novel NLRP3 Inhibitor. Molecules 2021;26:3975. [PMID: 34209843 DOI: 10.3390/molecules26133975] [Reference Citation Analysis]
10 Pellegrini C, Daniele S, Antonioli L, Benvenuti L, D'Antongiovanni V, Piccarducci R, Pietrobono D, Citi V, Piragine E, Flori L, Ippolito C, Segnani C, Palazon-Riquelme P, Lopez-Castejon G, Martelli A, Colucci R, Bernardini N, Trincavelli ML, Calderone V, Martini C, Blandizzi C, Fornai M. Prodromal Intestinal Events in Alzheimer's Disease (AD): Colonic Dysmotility and Inflammation Are Associated with Enteric AD-Related Protein Deposition. Int J Mol Sci 2020;21:E3523. [PMID: 32429301 DOI: 10.3390/ijms21103523] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 D'Antongiovanni V, Pellegrini C, Antonioli L, Benvenuti L, Di Salvo C, Flori L, Piccarducci R, Daniele S, Martelli A, Calderone V, Martini C, Fornai M. Palmitoylethanolamide Counteracts Enteric Inflammation and Bowel Motor Dysfunctions in a Mouse Model of Alzheimer's Disease. Front Pharmacol 2021;12:748021. [PMID: 34658885 DOI: 10.3389/fphar.2021.748021] [Reference Citation Analysis]
12 Li Y, Jiang MY, Chen JY, Xu ZW, Zhang JW, Li T, Zhang LL, Wei W. CP-25 exerts therapeutic effects in mice with dextran sodium sulfate-induced colitis by inhibiting GRK2 translocation to downregulate the TLR4-NF-κB-NLRP3 inflammasome signaling pathway in macrophages. IUBMB Life 2021;73:1406-22. [PMID: 34590407 DOI: 10.1002/iub.2564] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Guo L, Yang Y, Sheng Y, Wang J, Li W, Zhou X, Ruan S, Han C. Galloflavin Relieves the Malignant Behavior of Colorectal Cancer Cells in the Inflammatory Tumor Microenvironment. Front Pharmacol 2021;12:752118. [PMID: 34955826 DOI: 10.3389/fphar.2021.752118] [Reference Citation Analysis]
14 Song Y, Zhao Y, Ma Y, Wang Z, Rong L, Wang B, Zhang N. Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease. Cytokine Growth Factor Rev 2021;60:61-75. [PMID: 33773897 DOI: 10.1016/j.cytogfr.2021.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 D'Antongiovanni V, Pellegrini C, Benvenuti L, Fornai M, Di Salvo C, Natale G, Ryskalin L, Bertani L, Lucarini E, Di Cesare Mannelli L, Ghelardini C, Nemeth ZH, Haskó G, Antonioli L. Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis. Inflammation 2022. [PMID: 35338432 DOI: 10.1007/s10753-022-01663-8] [Reference Citation Analysis]
16 Zambom FFF, Oliveira KC, Foresto-Neto O, Faustino VD, Ávila VF, Albino AH, Arias SCA, Volpini RA, Malheiros DMAC, Saraiva Camara NO, Zatz R, Fujihara CK. Pathogenic role of innate immunity in a model of chronic NO inhibition associated with salt overload. Am J Physiol Renal Physiol 2019;317:F1058-67. [PMID: 31411073 DOI: 10.1152/ajprenal.00251.2019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Pellegrini C, Fornai M, Antonioli L, Blandizzi C, Calderone V. Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases. Int J Mol Sci 2019;20:E2876. [PMID: 31200447 DOI: 10.3390/ijms20122876] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
18 Wang D, Weng Y, Zhang Y, Wang R, Wang T, Zhou J, Shen S, Wang H, Wang Y. Exposure to hyperandrogen drives ovarian dysfunction and fibrosis by activating the NLRP3 inflammasome in mice. Sci Total Environ 2020;745:141049. [PMID: 32758727 DOI: 10.1016/j.scitotenv.2020.141049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Xie Z, Hui H, Yao Q, Duan Y, Li W, Cheng Y, Zhang M, Tian Y, Zhao G. By Regulating the NLRP3 Inflammasome Can Reduce the Release of Inflammatory Factors in the Co-Culture Model of Tuberculosis H37Ra Strain and Rat Microglia. Front Cell Infect Microbiol 2021;11:637769. [PMID: 33928044 DOI: 10.3389/fcimb.2021.637769] [Reference Citation Analysis]